NEW YORK — As the global medical community intensifies its efforts to eradicate type 1 diabetes (T1D), the role of multidisciplinary innovation has never been more critical. Breakthrough T1D, the leading global organization funding T1D research, has long maintained that a "world without T1D" requires more than just biological breakthroughs; it requires a constant influx of fresh perspectives and diverse expertise.
n
This summer, Breakthrough T1D concluded its 2026 Research Internship Program, a strategic initiative designed to mentor the next generation of scientific leaders while simultaneously advancing high-priority organizational projects. By integrating students from backgrounds ranging from biotechnology and biostatistics to global public health and clinical medicine, the program has produced a suite of tools and analyses that promise to streamline how the organization identifies, funds, and evaluates potential cures.
n
Main Facts: A Strategic Investment in Human Capital
n
The 2026 internship cohort arrived at a pivotal moment for Breakthrough T1D. Following the organization’s recent rebranding and its expanded focus on global screening and cell therapy, the Research department sought to leverage intern talent to fill specific data gaps and operational needs.
n
The program’s core philosophy is built on the premise that "fresh eyes" are essential for identifying systemic inefficiencies in research. This year’s interns were tasked with projects that were not merely educational but foundational to the organization’s long-term strategy. From mapping the global funding landscape to creating standardized frameworks for islet cell characterization, the outputs of the 2026 summer program are already being integrated into Breakthrough T1D’s operational workflows.
n
According to program leaders, the internship serves two primary functions: career development for the students and high-level analytical support for the Research team. By fostering interest in T1D among top-tier students at institutions like Columbia University, Cornell, and Binghamton University, the organization is effectively "seeding" the future of the field with experts who are already familiar with the complexities of the disease.
n
Chronology: From Orientation to Impact
n
The 2026 internship cycle followed a rigorous timeline designed to maximize both learning and productivity:
n
- n
- Early Spring 2026: Recruitment focused on identifying candidates with a mix of quantitative skills and a passion for mission-driven healthcare.
- June 2026: The cohort was onboarded and paired with senior mentors within the Research department. Unlike traditional internships, these roles were embedded directly within specific portfolios, such as Cell Therapy, Early Detection, and Clinical Research.
- July 2026 (Mid-Program): Interns moved from the data-gathering phase to the analysis and tool-development phase. This period involved cross-functional collaboration, with interns interviewing external investigators and industry partners.
- August 2026: The program culminated in a series of formal presentations to the Breakthrough T1D Research department. During these sessions, interns unveiled new databases, visualization tools, and policy frameworks that will guide the organization’s 2027 planning.
- Post-Summer 2026: The tools developed by the interns—such as the IDDP tracking database and the global clinical evidence map—have been transitioned to full-time staff for ongoing use.
n
n
n
n
n
n
Supporting Data: Five Pillars of Progress
n
The success of the 2026 program is best illustrated through the specific contributions of its five key interns, each of whom addressed a unique challenge within the T1D ecosystem.
n
1. Strengthening Industry Partnerships: Jihyun Park
n
Jihyun Park, a biotechnology master’s student at Columbia University, focused on the Industry Development and Discovery Partnerships (IDDP) Program. Since 2004, the IDDP has been a cornerstone of Breakthrough T1D’s venture philanthropy model, providing capital to companies to accelerate T1D therapies.
n
Park developed a comprehensive database of IDDP grantees, tracking their financial milestones, clinical progress, and eventual partnerships. By creating a visualization map of how these companies interact within the broader biotech industry, Park provided the Business Development team with a quantitative way to measure the long-term impact of their investments and identify "blind spots" where new partnerships could be forged.
n
2. Mapping the Global Funding Landscape: Sophia Meininger
n
Sophia Meininger, a T1D patient and public health student at Binghamton University, brought a personal and professional lens to the Program Management team. Her project involved a deep dive into the global funding ecosystem for T1D research.
n
Meininger identified government agencies, private foundations, and regional funders in emerging research hubs. Her findings highlighted regions where T1D research is taking shape but lacks centralized support. This data is vital for Breakthrough T1D’s mission to act as a global "connector," ensuring that researchers in disparate parts of the world can find the resources and collaborators they need.
n
3. Standardizing Cell Therapy: Aliaa Elkallini
n
Aliaa Elkallini, an M.D. candidate at the CUNY School of Medicine, addressed one of the most technical hurdles in the field: the characterization of manufactured islets. Cell therapy offers the potential to replace insulin-producing cells, but comparing results across different laboratories is notoriously difficult due to inconsistent reporting.
n
Elkallini developed two frameworks to standardize the "minimum information" required when reporting islet data. By interviewing investigators and reviewing decades of literature, she created a system that allows Breakthrough T1D to evaluate the "strength of evidence" for new approaches more objectively. This standardization is a prerequisite for moving cell therapies through the regulatory pipeline toward FDA approval.
n
4. Analyzing Early Detection and Screening: Avi Patel
n
Avi Patel, an MPH candidate at Long Island University with a background in clinical dentistry, worked within the Early Detection portfolio. As the medical community shifts toward universal screening for T1D autoantibodies, understanding the "how" and "where" of implementation is crucial.
n
Patel conducted a global landscape analysis of existing screening programs. Her work identified gaps in how screening results are delivered to families and how healthcare systems manage the transition from "at-risk" to a clinical diagnosis. Her perspective as a former clinician allowed her to pinpoint "point-of-care" barriers that often escape purely academic reviews.
n
5. Bridging the Gap in Clinical Trials: Kenzie Li
Kenzie Li, a Biostatistics and Data Science student at Weill Cornell Medicine, tackled the human element of research. Working with the Clinical Research team, Li analyzed the barriers that prevent patients from participating in clinical trials.
Beyond identifying current hurdles, Li launched a monumental project: a Global Clinical Evidence Map spanning from 1975 to 2026. This data-heavy initiative allows Breakthrough T1D to see where research has been concentrated and where it has been neglected. By visualizing 50 years of data, Li’s work enables the organization to direct future funding toward underrepresented populations and regions, ensuring that "breakthroughs" are accessible to everyone, regardless of geography.
Official Responses: A Symbiotic Relationship
The leadership at Breakthrough T1D emphasizes that the internship program is a two-way street of intellectual exchange.
"The summer interns bring a fresh perspective and creativity to their projects, giving us a better understanding of T1D and how to advance our mission," explained Matt Whipple, a Research Strategy Analyst and mentor to Sophia Meininger. Whipple noted that the interns’ ability to ask "why" regarding established protocols often leads to internal process improvements.
Racquel Enad, MS, MPH, Senior Manager of Research Partnerships & Alliances, echoed this sentiment. "Making progress toward our mission requires us to stay innovative, analytical, and open to learning. Training the next generation is important not only because we can help develop future leaders, but because we learn from them too. That exchange of ideas, perspectives, and curiosity helps move us closer to breakthroughs in T1D."
The mentorship provided by senior scientists like Dr. Nicholas Mamrak and Dr. Raquel Lopez Diez ensures that while the interns are contributing to the organization, they are also receiving high-level training in the "business of science"—a skill set often missing from traditional academic curricula.
Implications: The Future of T1D Leadership
The impact of the 2026 internship program extends far beyond the summer months. By the end of the program, Breakthrough T1D has not only gained five high-value analytical tools but has also influenced the career trajectories of five future leaders.
The implications for the T1D community are significant:
- Standardization: The frameworks developed by Elkallini could lead to faster regulatory reviews for cell therapies.
- Equity: The mapping work by Meininger and Li ensures that Breakthrough T1D remains a truly international organization, focusing on global health equity.
- Efficiency: The databases created by Park and Patel allow the organization to deploy donor dollars more effectively, targeting gaps in the market and the research landscape.
As these interns return to their respective universities and eventually enter the workforce as doctors, biostatisticians, and public health officials, they carry with them a deep understanding of the T1D landscape. Breakthrough T1D’s commitment to "more minds thinking about T1D" is a long-term play—one that recognizes that the cure for type 1 diabetes will not be found in a vacuum, but through the collaborative efforts of a diverse, highly trained, and energized global community.
The 2026 cohort has proven that when young talent is given the tools and the mentorship to tackle real-world problems, the distance between "research" and "cure" begins to shrink. Breakthrough T1D looks forward to the continued contributions of these rising stars as they transition from interns to colleagues in the fight against T1D.
